Business Wire

Prosimo Announces General Availability of AWS Cloud WAN Integration

Share

Prosimo, the Application Experience Infrastructure company, today announced the general availability of its integration with AWS Cloud WAN. This comes on the heels of AWS announcing today the general availability of AWS Cloud WAN. AWS Cloud WAN customers can now deploy the Prosimo platform to build an elastic and scalable Full Stack Cloud Transit for cross-region connectivity and segmentation to simplify and reduce operational burdens, deliver better experiences and lower costs.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220712005998/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

AWS Cloud WAN customers can now deploy the Prosimo platform to build an elastic and scalable Full Stack Cloud Transit for cross-region connectivity and segmentation to simplify and reduce operational burdens, deliver better experiences and lower costs. (Graphic: Business Wire)

"With these new features and functionality on the AXI Platform, Prosimo will be ideally suited to meet our goals: enable modern infrastructure capabilities using newer AWS networking constructs such as Cloud WAN, built-in observability for applications, and remove as much complexity as possible,” said Kevin Paige, CISO, Flexport

Enterprises can now simplify how they build and manage connectivity of their disparate environments across AWS regions across the globe, on-premises data centers, colocation facilities, branch offices, and their distributed user base with the combination of AWS Cloud WAN and Prosimo:

  • Achieve fine-grained elastic segmentation – The global network policy in AWS is kept coarse-grained and straightforward by design to be easy to manage and does not change that frequently. Fine-grained policy-based segmentation and security is the requirement from the application teams, in addition to the network layer segmentation. Prosimo helps to build policies at the per user and per-application level, on top of global network segments from Cloud WAN.
  • Hassle-free connectivity from AWS to any cloud – Regardless of how customers approach the core network policy, they will seek to achieve similar hassle-free connectivity to any of their DCs, other cloud providers, and edge co-locations. Prosimo helps extend the same core network policy model with segmentation to any cloud, including on-prem locations.
  • Modern cloud / NetDevOps operational model – Internal constituents such as modern cloud or NetDevOps teams will achieve a higher change frequency. With Prosimo’s APIs and Terraform modules, enterprise teams can integrate with their CI/CD flows for more agile development and deployment models while adhering to security and compliance guardrails and maintaining operational consistency.

Related Link: Sign up directly from the AWS Marketplace .

AWS Cloud WAN furthers Autonomous Multi-cloud Networking Solution

To ensure their multi-cloud environment is consistent, and easy-to-use, enterprises need to build an intelligent fabric that automatically connects applications, services, and networks across cloud infrastructures based on pre-set operations, security, and performance requirements. This requires first solving cloud connectivity issues then building an app transit layer that is autonomous and machine-driven to mitigate inherent complexity. Combining Network Transit and App Transit in a single architecture that simplifies and, most importantly, automates multi-cloud networking.

One Platform to Rule Them All

The combined network transit and app-to-app transit create a Full Stack Cloud Transit built on cloud-native constructs to take advantage of AWS’s global presence including AWS Cloud WAN. This gives enterprises a simpler connectivity model to migrate and connect their brownfield cloud deployments to deliver consistent, reliable, and secure Zero Trust-driven networks to support business-critical and latency-sensitive applications for users in any location.

“Our deepening relationship with AWS reflects the growing interest from AWS customers for simplified cloud networking solutions beyond just connectivity,” said Mani Ganesan, Head of Products, Prosimo. “AWS Cloud WAN and Prosimo offer a seamless and tightly integrated autonomous cloud networking solution as enterprises continue their enterprise cloud journeys and modernize their infrastructure.”

Resources

Connect with Prosimo

About Prosimo:

Prosimo delivers simplified multi-cloud infrastructure for distributed enterprise cloud journeys. Companies innovate faster and remain in control with the Prosimo integrated stack. This stack combines cloud networking, performance, security, observability, and cost management—all powered by data insights and machine learning models with autonomous cloud networking to reduce complexity and risk. Cloud-forward enterprises, including F100, have adopted Prosimo to successfully roll out revenue-generating applications, improve operational efficiency, and accelerate positive business outcomes. Prosimo is venture-backed by marquee investors such as General Catalyst and WRVI Capital. For more information, visit https://www.prosimo.io.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press and Analyst Contact:
Matt Stubbs
Outside Labs for Prosimo
(801) 703-6626
press@prosimo.io

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 10:00:00 EET | Press release

Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of

Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 09:44:00 EET | Press release

Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi

Incyte Japan Announces Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer22.12.2025 09:42:00 EET | Press release

Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). "Today's approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan G.K. "By offering combination therapy with chemotherapy, Zynyz provides a vital new path forward for patients facing this challenging disease, addressing a significant unmet need in cancer care for patients with SCAC and their families." The approval was based on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with platinum-based chemotherapy (carboplatin-paclitaxel) in adult patients with metastatic or inoperable

GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published22.12.2025 09:30:00 EET | Press release

Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and is based exclusively on publicly available information. The content, assumptions and conclusions of the report are solely attributable to the analyst. The GBC AG analyst coverage report is available on the Company’s official website at the following address: https://mexedia.com/en/financial-statements-and-reports/ and on the analyst’s website. Daniel Gilcher, Chief Financial Officer of Mexedia S.p.A. Società Benefit, stated: “The completion and publication of the analyst coverage report by GBC AG represents the conclus

Hisense Joins HEVC Advance Patent Pool22.12.2025 04:06:00 EET | Press release

Access Advance LLC, the global leader in video codec patent pool licensing, today announced that Hisense Group Holdings Co., Ltd. has joined the HEVC Advance Patent Pool as a Licensee. Hisense joins the recent additions to the Access Advance patent pools, including Xiaomi, MSI, Transsion, and expanded relationships with Huawei, HP and Sharp. Hisense, headquartered in Qingdao, China, is one of the world's largest television manufacturers, with a global presence spanning Asia, Europe, the Americas, and beyond. The company's products reach consumers in more than 160 countries and regions worldwide. "We are pleased to welcome Hisense to the HEVC Advance Patent Pool," said Peter Moller, CEO of Access Advance. "This agreement is the result of extensive engagement between our teams over a considerable period of time. Hisense's decision to join the pool reflects a recognition that transparent, efficient licensing solutions benefit both innovators and implementers across the video technology ec

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye